Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Colorectal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Colorectal Cancer
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Colorectal Cancer 11/26/2008 - (DGNews)
    TopAbstracts in Colorectal Cancer 11/12/2008 - (DGNews)
    Imaging Surveillance of Small Polyps, an Alternative to Immediate Colonoscopy - (DGNews)
    TopAbstracts in Colorectal Cancer 10/29/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Colorectal Cancer
  • Treatment of Advanced Colorectal Cancer: What Are the Clinical Implications of Latest Data?
  • Update on Targeted Therapies in mCRC: How to Choose to Maximize Efficacy and Minimize Toxicity
  • Interpreting Current Evidence in mCRC: Progress Towards Individualized Therapy
  • Colorectal Cancer Screening and Prevention

    Webcasts/CME archive

     Recent cases - Colorectal Cancer
      Metastatic Colorectal Cancer to a Primary Thyroid Cancer
      Late Recurrence of Large Peri-Stomal Metastasis Following Abdomino-Perineal Resection of Rectal Cancer
      Cytomegalovirus Colitis in a Patient with Recurrent Colon Cancer After Systemic Chemotherapy: A Case Report
      Solitary Mediastinal Lymph Node Metastasis in Rectosigmoid Carcinoma: A Case Report
      Pulmonary Lymphangitic Carcinomatosis as a Primary Manifestation of Colon Cancer in a Young Adult

      Cases archive
        




      my personal edition > colorectal cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Oxaliplatin Plus 5-Fluorouracil and Leucovorin Combination Effective in Second-Line Metastatic Colorectal Cancer Treatment: Presented at ASCO

      By Ed Susman

      CHICAGO, IL -- June 2, 2003 -- Researchers presenting final data from a large clinical trial said that adding oxaliplatin to standard second-line treatment for metastatic colorectal cancer significantly increased response rates, time to progression, and symptom relief.

      The study, which was the pivotal trial that resulted in licensing of oxaliplatin for treatment of advanced colorectal cancer, enrolled 821 patients who received standard second-line therapy -- infusional 5-fluorouracil (5-FU) and leucovorin -- or oxaliplatin alone, or a combination of oxaliplatin, 5-FU, and leucovorin (FOLFOX4).

      "The ability of FOLFOX4 to delay tumor progression and relieve cancer-related symptoms is clinically meaningful to our patients," said Mace Rothenberg, MD, professor of medicine at the Vanderbilt-Ingram Cancer Center, in Nashville, Tennessee, at the 39th Annual Meeting of the American Society of Clinical Oncology.

      Dr. Rothenberg said the trial found that 9.6% of patients receiving FOLFOX4 showed a clinical response compared with 0.7% of patients receiving 5-FU/leucovorin (P < 0.0001).

      The time to progression was 5.6 months on FOLFOX4 compared with 2.6 months on 5-FU/leucovorin, which also was significant at the P < 0.0001 level. Tumour-related symptoms such as weight loss, abdominal pain, weakness, and fatigue were relieved in about 28% of the FOLFOX4 patients compared with 15% of the patients on 5-FU/leucovorin (P = 0.002).

      The use of oxaliplatin as a single agent did not prove effective in these patients, Dr. Rothenberg said.

      Robert Mayer, MD, professor of medicine at Harvard Medical School and director of gastrointestinal oncology at Dana Farber Cancer Institute, in Boston, Massachusetts, said, "I think this study will have a great impact for use as a second-line treatment in these colon cancer patients."

      The use of oxaliplatin was approved for second-line treatment of metastatic colorectal cancer if those patients progressed while being treated with irinotecan and a bolus injection of 5-FU/leucovorin.

      The study was supported by Sanofi-Synthelabo and was conducted by the North Central Cancer Treatment Group, based at the Mayo Clinic in Rochester, Minnesota.


      [Study title: Final Results of a Phase III Trial of 5-FU/Leucovorin Versus Oxaliplatin Versus the Combination in Patients With Metastatic Colorectal Cancer Following Irinotecan, 5-FU, and Leucovorin. Abstract 1011]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send